摘要
目的检测不同肝功能损伤及并发癌栓的肝癌患者血浆中D二聚体(D-dimer,D-D)含量以及抗凝血酶(antithrombin,AT)活性,探讨两者在肝癌患者中的关系及临床应用。方法采用法国Stago公司STA-R Evolution全自动血凝仪对182例肝癌(包括肝癌合并肝硬化、癌栓)患者、26例慢性肝病患者、30例健康对照者进行D-D含量以及AT活性的检测。结果肝癌组、慢性肝病组与健康对照组比较有显著差异(P<0.05);慢性肝病、肝癌Ⅰ、Ⅱ期组间比较无显著差异(P>0.05),肝癌Ⅱ、Ⅲ、Ⅳ期组间比较有显著差异(P<0.05);合并肝硬化代偿组与合并肝硬化失代偿组间比较有显著差异(P<0.05),与肝癌组间比较无显著差异(P>0.05);合并门静脉癌栓组与肝癌无癌栓组间比较有显著差异(P<0.05)。结论肝癌患者血浆中D-D含量及AT活性与肝功能损伤程度呈正相关。定期监测D-D及AT活性对肝癌患者癌栓形成的评估有参考价值。
Objective Detecting D- dimer （ D- D） quantitatively and antithrombin （AT） activity of the liver cancer patients, the purpose of this research was to find the relationship of them in those liver cancer pa- tients with different liver function injury. Methods 182 patients with hepatic cancer（ including hepatic carci- noma with liver cirrhosis, carcinoma bolt） ,26 patients of chronic liver disease and 30 cases of healthy people were detected D-D quantitation and AT activity respectively using the French Stago company STA-R Evolution fully automatic blood clots meter. Results The result show statistical signification （ P 〈 0.05 ） were these groups ： Liver cancer, chronic liver disease group and healthy group ; Liver cancer Ⅱ , Ⅲ, Ⅳ groups; Merge cir- rhosis compensatory and merge decompensated liver cirrhosis groups;Complicated with portal venous tumor emboli group and liver cancer without carcinoma bolt among groups. The other groups don＇ t show any statisti- cal signification （ P 〉 0.05 ）, including ： Chronic liver disease, and liver cancer Ⅰ , Ⅱ groups, Merge cirrhosis compensatory group and liver cancer. Conclusion The quantitation of D-D and AT activity show positive re- lation with liver function of the liver cancer patients. This study remind that it is necessary to monitor the quan- titation of D-Dand AT activity of liver cancer patients, especially the patients with carcinoma bolt formation.
出处
《血栓与止血学》
2013年第1期27-29,31,共4页
Chinese Journal of Thrombosis and Hemostasis
关键词
D二聚体
抗凝血酶
肝癌
肝硬化
D- dimer
Antithrombin
Liver cancer
Cirrhosis
